Faculty of Health Science كلية العلوم الصحيه

Permanent URI for this community

Now showing 1 - 1 of 1

A Case of Antithyroid Drug-Induced Agranulocytosis Pre-Covid 19 Era
(جامعة الشيخ عبدالله البدري, 2020) Sufian K. M. Noor; , Mosab Nouraldein Mohammed Hamad; , Sarra Osman Bushara; , Amel Abdalrhim Sulaiman3; Mohamed Adil Yassen Ali4; , Remaz Khalid Hassan Ahmed4; , Almotasim Mohamed Aabdelmgid Elnaema; Samaher Mozamil Mohamed Abdelrahim
Agranulocytosis is an infrequent and serious side effect of antithyroid drugs characterized by a noticeable reduction in granulocyte and neutrophil count, it usually occurs within the first 2-3 months of treatment. There is a variety of mechanisms by which ATD can induce agranulocytosis, direct drug effects, and immunological mechanisms. We present 33 years old female attended Atbara teaching hospital who has developed agranulocytosis 2 weeks after starting ATD to treat relapsed Graves’ disease. What was unusual about this patient is that symptoms have occurred in a period less than 15 days of starting treatment and with a dose of 45 mg/day. The physician must educate the patient about the possibility of early onset of serious side effects of ATD and to seek medical advice as soon as possible